CPRX - Insider Transaction: Jeffrey Del Carmen Sells $121K Worth Of Catalyst Pharmaceuticals Shares | Benzinga
Jeffrey Del Carmen, Chief Commercial Officer at Catalyst Pharmaceuticals (NASDAQ:CPRX), executed a substantial insider sell on June 11, according to an SEC filing.
What Happened: Carmen opted to sell 7,541 shares of Catalyst Pharmaceuticals, according to a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The transaction's total worth stands at $121,183.
In the Wednesday's morning session, Catalyst Pharmaceuticals's shares are currently trading at $15.76, experiencing a up of 1.29%.
Get to Know Catalyst Pharmaceuticals Better
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Understanding the Numbers: Catalyst Pharmaceuticals's Finances
Revenue Growth: Catalyst Pharmaceuticals displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 15.4%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care ...